Skip to main content
SpringerLink
Log in

Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Ghrelin, the recently identified hormone with GH-secreting and appetite-inducing effects, acts on the GH secretagogue receptor (GHS-R). GHS-R belongs to the G protein-coupled 7 transmembrane domain receptors and activates the phospholipase C pathway; it then leads to the release of GH from somatotroph cells via an elevation of intracellular calcium concentration. Both in vivo and in vitro studies demonstrated that the effect of GH secretagogues (GHS) could be desensitised similar to most receptor stimulation systems. We have studied whether acute desensitisation of the GHS-R occurs in response to the GHS hexarelin in vitro in terms of intracellular calcium concentration. Chinese hamster ovary cells were transiently transfected with cDNA encoding the human type 1a GHS-R. The presence of messenger RNA was confirmed with RT-PCR, while no GHSR was observed in mock-transfected cells. Calcium responses to the peptide GHS analogue hexarelin were measured using the fluorescent indicator fura-2. Cells were stimulated with the peptide GHS, hexarelin, at concentrations between 10−10 and 10−7 M. Cells transfected with the GHS-R cDNA demonstrated a significant and specific calcium response to hexarelin that was not observed in mock-transfected cells. Marked desensitisation of the calcium response to hexarelin was observed 2-5 min after the first dose of hexarelin (10−7 M) was administered. These data show directly for the first time the desensitisation of the GHS receptor signal at the second messenger level. The desensitisation of the receptor may play a major role in the regulation of effect of circulating or locally produced ghrelin both in the GH and in the appetite-regulating system or in other systems where ghrelin has been shown to be active, such as the cardiovascular system or cell proliferation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growthhormone- releasing acylated peptide from stomach. Nature 1999, 402: 656–60.

    Article  PubMed  CAS  Google Scholar 

  2. Collins S, Caron MG, Lefkowitz RJ. From ligand binding to gene expression: new insights into the regulation of G-protein- coupled receptors. Trends Biochem Sci 1992, 17: 37–9.

    Article  PubMed  CAS  Google Scholar 

  3. Badger TM, Millard WJ, McMormick GF, Bowers CY, Martin JB. The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 1984, 115: 1432–8.

    Article  PubMed  CAS  Google Scholar 

  4. Cheng J, Wu TJ, Butler B, Cheng K. Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci 1997, 60: 1385–92.

    Article  PubMed  CAS  Google Scholar 

  5. Yoshihara F, Kojima M, Hosoda H, Nakazato M, Kangawa K. Ghrelin: a novel peptide for growth hormone release and feeding regulation. Curr Opin Clin Nutr Metab Care 2002, 5: 391–5.

    Article  PubMed  CAS  Google Scholar 

  6. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites. J Endocrinol 1991, 129: 11–9.

    Article  PubMed  CAS  Google Scholar 

  7. Klinger B, Sibergeld A, Deghenghi R, Frenkel J, Laron Z. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996, 134: 716–9.

    Article  PubMed  CAS  Google Scholar 

  8. Rahim A, O’Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998, 83: 1644–9.

    Article  PubMed  CAS  Google Scholar 

  9. Rahim A, Shalet SM. Does desensitisation to growth hormone secretagogues occur? In: Dieguez C, Ghigo E, Boghen MF, Casanueva FF eds. Growth hormone secretagogues: Basic findings and clinical implications. Rotterdam: Elsevier 1999, 175–81.

    Chapter  Google Scholar 

  10. Freir S, Weiss O, Eran M, et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999, 44: 704–8.

    Article  Google Scholar 

  11. Bohm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J 1997, 322: 1–18.

    PubMed Central  PubMed  CAS  Google Scholar 

  12. Freedman NJ, Lefkowitz RJ. Desensitization of G protein-coupled receptors. Recent Prog Horm Res 1996, 51: 319–51.

    PubMed  CAS  Google Scholar 

  13. Korbonits M, Jacobs RA, Aylwin SJB, et al. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. J Clin Endocrinol Metab 1998, 83: 3624–30.

    PubMed  CAS  Google Scholar 

  14. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985, 260: 3440–50.

    PubMed  CAS  Google Scholar 

  15. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273: 974–7.

    Article  PubMed  CAS  Google Scholar 

  16. Cheng K, Chan WW, Butler B, Barreto A Jr., Smith RG. Evidence for a role of protein kinase-C in His-D-Trp-Ala-Trp- D-Phe-Lys-NH2-induced growth hormone release from rat primary pituitary cells. Endocrinology 1991, 129: 3337–42.

    Article  PubMed  CAS  Google Scholar 

  17. Herrington J, Hille B. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by 2 mechanisms. Endocrinology 1994, 135: 1100–8.

    PubMed  CAS  Google Scholar 

  18. Dickson SL, Leng G, Dyball REJ, Smith RG. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinol 1995, 61: 36–43.

    Article  CAS  Google Scholar 

  19. Smith RG, Van der Ploeg LHT, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocrine Rev 1997, 18: 621–45.

    Article  CAS  Google Scholar 

  20. Pong SS, Chaung L-YP, Dean CD, et al. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 1996, 10: 57–61.

    PubMed  CAS  Google Scholar 

  21. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic heptapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984, 114: 1537–45.

    Article  PubMed  CAS  Google Scholar 

  22. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991, 128: 2027–35.

    Article  PubMed  CAS  Google Scholar 

  23. Jacks T, Hickey GJ, Taylor J, et al. Effects of acute and repeated intravenous administration of L-692,585, a novel nonpeptidyl growth hormone secretagogue, on plasma growth hormone, ACTH, cortisol, prolactin, Thyroxin (T4), insulin and IGF-1 levels in beagles. Proc of the 77th Annual Meet of the Endocrine Soc 1994, 660: (abstract)

  24. Laron Z, Frenkel J, Deghenghi R, et al. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf) 1995, 43: 631–5.

    Article  CAS  Google Scholar 

  25. Mericq V, Cassorla F, Salazar T, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab 1998, 83: 2355–60.

    PubMed  CAS  Google Scholar 

  26. Fairhall KM, Mynett A, Smith RG, Robinson ICAF. Consistent GH responses to repeated injections of GH-releasing hexapeptide (GHRP-6) and the nonpeptide GH secretagogue, L-692,585. J Endocrinol 1995, 145: 417–26.

    Article  PubMed  CAS  Google Scholar 

  27. DeBell WK, Pezzoli SS, Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation. J Clin Endocrinol Metab 1991, 72: 1312–6.

    Article  PubMed  CAS  Google Scholar 

  28. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO. Twentyfour- hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993, 76: 1202–8.

    PubMed  CAS  Google Scholar 

  29. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993, 77: 1641–7.

    PubMed  CAS  Google Scholar 

  30. Nijland EA, Strasburger CJ, PoppSnijders C, vanderWal PS, Van der Veen EA. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide- 2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. Eur J Endocrinol 1998, 139: 395–401.

    Article  PubMed  CAS  Google Scholar 

  31. Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001, 86: 1116–25.

    PubMed  CAS  Google Scholar 

  32. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002, 87: 2988.

    Article  PubMed  CAS  Google Scholar 

  33. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003, 37: 649–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, St. Bartholomew’s Hospital, Dominion House, Unit 1.1, 59 Bartholomew Close, London, EC1A 7BE, UK

    R. D. Orkin, D. Norman, S. L. Chew, A. J. L. Clark, A. B. Grossman & Márta Korbonits MD, PhD MRC

  2. Department of Nephrology, St. Bartholomew’s Hospital, London, UK

    D. I. New

Authors
  1. R. D. Orkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. I. New
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Norman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. L. Chew
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. J. L. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. B. Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Márta Korbonits MD, PhD MRC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Márta Korbonits MD, PhD MRC.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orkin, R.D., New, D.I., Norman, D. et al. Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro . J Endocrinol Invest 26, 743–747 (2003). https://doi.org/10.1007/BF03347357

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347357

Key-words

Search

Navigation